Attovia Therapeutics (ATTO) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($744.6 million vs $662.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | PROK |
|---|---|---|
| Share price | $16.31 | $1.66 |
| Market cap | $744.57M | $662.64M |
| 1-day change | -0.67% | +5.73% |
| YTD return | — | -29.91% |
| 1-year return | — | -46.96% |
| 5-year return | — | -84.09% |
| EPS (TTM) | $-2.74 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $3.48 |
| 52-week low | $15.48 | $1.30 |
| Distance from 52-week high | -41.75% | -52.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +158.74% | +276.51% |
| Average volume | 458.24K | 1.30M |
| Shares outstanding | 45.65M | 208.93M |
| Employees | 44 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
ATTO vs PROK FAQ
Which is bigger, Attovia Therapeutics or ProKidney?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $744.57M compared with $662.64M for ProKidney (PROK).
Are Attovia Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.